이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biodesix 대차 대조표 상태

재무 상태 기준 확인 3/6

Biodesix 의 총 주주 지분은 $-5.5M 이고 총 부채는 $35.6M, 이는 부채 대 자기자본 비율을 -646.2% 로 가져옵니다. 총자산과 총부채는 각각 $87.2M 및 $92.7M 입니다.

주요 정보

98.9%

부채 비율

US$35.84m

부채

이자 보상 비율	n/a
현금	US$42.22m
주식	US$36.26m
총 부채	US$79.58m
총 자산	US$115.84m

최근 재무 상태 업데이트

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

재무 상태 분석

단기부채: BDSX 의 단기 자산 ( $57.6M )이 단기 부채( $17.6M ).

장기 부채: BDSX 의 단기 자산( $57.6M )은 장기 부채( $62.0M ).

부채 대 자본 내역 및 분석

부채 수준: BDSX 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: BDSX 은 5년 전에 마이너스 주주 지분을 가졌으나 지금은 플러스이므로 개선되었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BDSX 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: BDSX 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Biodesix 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Biodesix, Inc. Announces Impactful Clinical Data on the Primary Immune Response Test at IASLC 2022 Therapies of Lung Cancer Meeting

Biodesix, Inc. to Report Q4, 2021 Results on Mar 14, 2022

Biodesix, Inc. Launches GeneStrat NGS Test and the IQLung Testing Strategy